ResMed Inc. $RMD Shares Sold by Swiss National Bank

Key Points

• Swiss National Bank trimmed its ResMed stake by 4.9% in Q3, selling 21,900 shares and leaving it with 422,700 shares (about 0.29% of the company) valued at roughly $115.7 million.
• ResMed beat quarterly estimates, reporting $2.81 EPS vs. $2.68 expected and $1.42B in revenue (vs. $1.40B), with revenue up 11% year‑over‑year and analysts holding a consensus "Moderate Buy" rating and a ~$299 target.
• Insiders have been net sellers, offloading 16,082 shares (~$4.15M) in the last three months — including sales by a director and the CEO — while the company pays a $0.60 quarterly dividend (1.0% yield).

Swiss National Bank reduced its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 4.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 422,700 shares of the medical equipment provider's stock after selling 21,900 shares during the quarter. Swiss National Bank owned about 0.29% of ResMed worth $115,706,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of RMD. SJS Investment Consulting Inc. grew its stake in shares of ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 86 shares during the period. WFA of San Diego LLC purchased a new stake in ResMed during the second quarter worth about $26,000. Westside Investment Management Inc. increased its holdings in ResMed by 100.0% in the third quarter. Westside Investment Management Inc. now owns 132 shares of the medical equipment provider's stock valued at $36,000 after buying an additional 66 shares in the last quarter. GoalVest Advisory LLC purchased a new position in ResMed in the third quarter valued at about $37,000. Finally, IMA Advisory Services Inc. lifted its position in shares of ResMed by 52.7% during the 3rd quarter. IMA Advisory Services Inc. now owns 139 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 48 shares during the period. Hedge funds and other institutional investors own 54.98% of the company's stock.

ResMed Stock Down 2.3%

Shares of NYSE:RMD opened at $246.99 on Wednesday. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 0.06. ResMed Inc. has a 52-week low of $199.92 and a 52-week high of $293.81. The stock's fifty day simple moving average is $255.50 and its 200-day simple moving average is $259.25. The company has a market capitalization of $35.98 billion, a P/E ratio of 24.43, a P/E/G ratio of 1.68 and a beta of 0.88.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.13. The firm had revenue of $1.42 billion during the quarter, compared to analysts' expectations of $1.40 billion. ResMed had a return on equity of 25.20% and a net margin of 27.53%.The firm's quarterly revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.43 EPS. As a group, equities research analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Thursday, February 12th. ResMed's payout ratio is currently 23.74%.

Insider Activity at ResMed

In related news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $260.22, for a total transaction of $520,440.00. Following the sale, the director owned 62,773 shares in the company, valued at approximately $16,334,790.06. This trade represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $273.78, for a total transaction of $1,366,435.98. Following the completion of the sale, the chief executive officer directly owned 466,223 shares of the company's stock, valued at $127,642,532.94. The trade was a 1.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 16,082 shares of company stock worth $4,152,307 in the last three months. Insiders own 0.65% of the company's stock.

Wall Street Analyst Weigh In

RMD has been the topic of a number of research reports. Piper Sandler upped their price target on ResMed from $270.00 to $275.00 and gave the stock a "neutral" rating in a report on Friday, January 30th. Robert W. Baird set a $281.00 target price on ResMed in a research report on Friday, January 30th. Stifel Nicolaus upped their target price on ResMed from $260.00 to $265.00 and gave the company a "hold" rating in a report on Friday, January 30th. Weiss Ratings raised ResMed from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Monday, February 9th. Finally, Citigroup boosted their price objective on shares of ResMed from $330.00 to $345.00 and gave the stock a "buy" rating in a research report on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $299.27.

ResMed Company Profile

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.